Preclinical Testing CRO

Show more...

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron – ScienceDirect

Vaccine protection against the SARS-CoV-2 Omicron variant in macaques: Cell

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.

SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.

Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters.

A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant.

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.

BIAL Award in Biomedicine distinguishes research which is the basis of two of the vaccines against COVID-19.  

To see award video, please click here.

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans.

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.

Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques.

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.

Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques.

Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection.

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice.

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.

In Vitro Activity of Cysteamine Against SARS-CoV-2 Variants Alpha, Beta,Gamma and Delta

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.

One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization.

Correlates of protection against SARS-CoV-2 in rhesus macaques

Scientific publication to be published soon – Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

REGN-COV2 Antibodies Prevent and Treat SARS-CoV-2 Infection in Rhesus Macaques and Hamsters

Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques

BIOQUAL Announces Publication of an Investigational COVID-19 vaccine candidate that prevents severe clinical disease in animals

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Potently neutralizing and protective human antibodies against SARS-CoV-2

Development of a potent Zika virus vaccine using self-amplifying messenger RNA

BIOQUAL Announces Publication New England Journal Medicine. August, 10, 2020

Press Release, BIOQUAL, Inc. July 31, 2020 Rockville

Bioqual is proud to have been associated with the development of an effective vaccine against the Ebola virus recently licensed for use in humans by the European Commission

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Anti-PfGARP Activates Programmed Cell Death of Parasites and Reduces Severe Malaria

Microbial Dysbiosis during SIV Infection is Partially Reverted with Combination Anti-retroviral Therapy

BIOQUAL involved in the fight against COVID-19



is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and has a long history of providing state-of-the-art facilities and trained, experienced research scientists, veterinarians and animal care personnel for clients involved in infectious disease investigations, cancer research, and a wide variety of other in vivo and In vitro studies.

Research Services






Other Infectious Disease Areas

BIOQUAL’s laboratories are actively involved in the evaluation of vaccines, vaccine therapeutics, microbicides and drug therapies. In vitro services are available. These services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays.